Rather than selecting PRMT1 a priori, we identified it through a targeted CRISPR/Cas9 screen of ~ 200 DNA damage response genes, providing unbiased and orthogonal validation of its essential role in MM survival. The gene discussed is PRMT1; the disease is Miyoshi myopathy.